Form 4: Teladoc CLO Exercises Units, Sells Shares for Tax

Teladoc Health's Chief Legal Officer, Adam C. Vandervoort, converted performance and restricted stock units into common stock and subsequently sold a portion to cover tax obligations.

Summary

• Adam C. Vandervoort, Teladoc Health's Chief Legal Officer and Secretary, reported transactions involving the company's common stock.
• On August 29, 2025, 1,505 performance stock units (PSUs) converted into common stock, increasing his direct beneficial ownership to 71,278 shares.
• Also on August 29, 2025, 4,418 restricted stock units (RSUs) converted into common stock, bringing his direct beneficial ownership to 75,696 shares.
• A further 5,350 restricted stock units (RSUs) converted into common stock on August 29, 2025, increasing his direct beneficial ownership to 81,046 shares.
• On September 2, 2025, Mr. Vandervoort sold 5,867 shares of common stock at a price of $7.585 per share.
• This sale was conducted to cover tax withholding obligations related to the vesting of his performance stock unit and restricted stock unit awards, reducing his direct beneficial ownership to 75,179 shares.

Sentiment

Score: 5

Explanation: The transactions represent routine executive compensation activities, including the conversion of vested stock units into common stock and a subsequent sale of shares to cover tax obligations, which is a common practice and does not indicate a change in company fundamentals or management's long-term view.

Positives

• The vesting and conversion of performance and restricted stock units indicate the fulfillment of executive compensation incentives, aligning management interests with shareholder value creation over time.
• The conversion of units into common stock increases the executive's direct ownership in the company prior to the tax-related sale.

Negatives

• The sale of 5,867 shares, even for tax purposes, results in a reduction of the Chief Legal Officer's direct beneficial ownership in Teladoc Health.

Future Outlook

NA

Management Comments

• Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance stock unit and restricted stock unit awards.

Industry Context

This filing details a routine insider transaction for an executive at Teladoc Health, a leading company in the telehealth industry. Such transactions are common across all industries as part of executive compensation and tax planning, and do not inherently reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but the transactions are routine and unlikely to significantly impact shareholder sentiment or company valuation.
• Employees (Executive): The vesting and conversion of stock units represent the realization of compensation, which is a positive for the executive.

Next Steps

• The remainder of the 1,505 performance stock units will vest in eight substantially equal quarterly installments after March 1, 2024.
• The remainder of the 4,418 restricted stock units (from the March 3, 2023 grant) will vest in eight substantially equal quarterly installments after March 1, 2024.
• The remainder of the 5,350 restricted stock units will vest in eight substantially equal quarterly installments beginning on June 1, 2025, after the first anniversary of the grant date.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically the conversion of vested stock units and a subsequent sale of shares to cover tax liabilities. Such transactions are common and do not typically provide sufficient information to alter an investment thesis. Therefore, a 'hold' recommendation is appropriate, pending further fundamental analysis of Teladoc Health's business performance and market conditions.

Keywords

Teladoc Health, TDOC, Insider Transaction, Form 4, Executive Compensation, Stock Units, Restricted Stock Units, Performance Stock Units, Adam C. Vandervoort